

19 Jun 2023 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: new IRA concerns and legal action in the US; Biogen brings in another ex-Sanofi exec; Novartis buys into kidney disease; and China appears to be raising the regulatory bar in the immune-oncology space.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 16 June 2023, including: new IRA concerns and legal action in the US; [Biogen, Inc.](#) brings in another ex-[Sanofi](#) exec; [Novartis AG](#) buys into kidney disease; and China appears to be raising the regulatory bar in the immune-oncology space.

This and all our other podcasts are available on the Pharma Intelligence channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Lilly Sidelined Three Drugs Due To IRA, CEO Ricks Says](#)" - Scrip, 14 Jun, 2023.)

(Also see "[What To Expect As IRA Legal Challenges Mount](#)" - Scrip, 12 Jun, 2023.)

(Also see "[Biogen's Adam Keeney Focuses On Dealmaking As Growth Strategy Is Made Over](#)" - Scrip, 13 Jun, 2023.)

(Also see "[Novartis Aims To Fly High In Kidney Disease With Chinook Buy](#)" - Scrip, 12 Jun, 2023.)

(Also see "[Chinese Regulator Rejects Domestic PD-1/L1 Contender In Latest Tightening Signal](#)" -

Scrip, 14 Jun, 2023.)

[Click here to explore this interactive content online](#) ✨